Step into the spotlight with four penny stocks that have caught our attention due to their potential for a rebound. These stocks have exhibited intriguing recent movements and possess unique attributes that could contribute to a potential resurgence. While their current valuations are lower, these four companies hold some qualities that might position them for upward mobility. 

Epazz, Inc. (OTC: EPAZ) 

Epazz, Inc., and its subsidiary, ZenaDrone, Inc., are two dynamic entities making significant waves in the tech sector. Epazz Inc. is a leading provider of cloud-based software solutions, catering to a wide spectrum ranging from corporate enterprises to higher education institutions and the public sector. 

ZenaDrone Inc., a subsidiary of Epazz, stands as an embodiment of innovation. The company specializes in intelligent unmanned aerial vehicle technology, incorporating machine learning software and AI. What started as a venture to revolutionize the hemp farming sector swiftly evolved into a multifunctional industrial surveillance, inspection, and monitoring solution. Their predictive AI analytics, utilizing methods like machine learning algorithms and statistical modeling, enable data-driven forecasting.

On August 24, 2023, Epazz Inc. revealed a game-changing development. ZenaDrone Inc. is actively finalizing a strategic joint venture in Brazil aimed at creating an operational stronghold for ZenaDrone 1000's "Drone as a Service" operations. This venture is set to cater to offshore oil rigs, cattle ranches, and governmental bodies, marking ZenaDrone's dedication to pioneering solutions.

The impact could be profound; the introduction of the first batch of 10 drones from a Dubai manufacturing facility is projected to yield over $150,000 per drone annually. ZenaDrone's unique applications in large-scale farming, government initiatives, and oil rig operations place this venture on a distinctive pedestal.

CEO Shaun Passley, Ph.D., highlights the broader strategy: "We are expanding via international joint ventures. We are also working on South Africa and India joint ventures."

In conclusion, the recent update encapsulates the essence of Epazz and ZenaDrone's dedication to innovation. The joint venture's potential for reshaping drone services and increasing market influence resonates through their initiatives, setting the stage for a potential rebound. As the market acknowledges their forward momentum, Epazz could well emerge as a compelling bounce play in the tech sector.

Solar Integrated Roofing Corp. (OTC: SIRC)

SIRC stands as a pioneering provider of comprehensive solar power, roofing, and EV charging solutions for both commercial and residential properties across North America. The company is dedicated to delivering optimal experiences through a commitment to innovation and legacy-driven leadership.

In a recent update, SIRC showcased its ongoing progress and important accomplishments, including:

• PLEMCo, a subsidiary of SIRC, achieved a remarkable feat with the successful completion of 14 EVSE Projects in LA County thus far in 2023. Notably, four additional projects are currently in the construction phase.
• The Calaway Farms project marked a significant milestone as the design and engineering phases concluded. Construction is anticipated to commence in the latter half of 2023, underscoring SIRC's commitment to consistent advancement.
• SIRC's Shared Services, Financial Services, and Supplemental Claims Services Division (Balance) reported a substantial 32.9% increase in revenue during the second quarter of 2023 compared to the corresponding period last year. Noteworthy is Balance's achievement of over doubling the number of net new revenue-generating clients from the first quarter. Additionally, a net profit margin exceeding 26% for the first half of fiscal year 2023 highlights the division's prowess.

Brad Rinehart, Chief Executive Officer of SIRC, emphasized the company's steadfast approach: "We are continuing to execute across our core operational initiatives while maintaining a robust project contract pipeline. The demand for EV charging stations and renewable energy solutions continues to be substantially higher than what is currently available, which creates a massive scaling opportunity for SIRC. As we approach being cash flow positive, we are focused on generating revenue growth across all verticals while improving our cost overhead and reducing our short-term debt to strengthen our balance sheet."

Rinehart also highlighted the collaborative efforts with Tribeca Energy, emphasizing SIRC's role in a vertically integrated enterprise aimed at decarbonizing the global energy grid. With a diligent management team in place, SIRC is dedicated to advancing its operating strategy and creating enduring value for shareholders.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)

Adamis is a biopharmaceutical company with a focus on advancing treatments for opioid overdose and substance use disorders. The company's FDA-approved products, ZIMHI for opioid overdose and SYMJEPI for acute allergic reactions, showcase its commitment to addressing critical medical needs.

In a significant move, Adamis completed a merger with DMK Pharmaceuticals, a clinical-stage biotech company. This alliance positions Adamis to develop groundbreaking therapies for opioid use disorder (OUD) and other neurological conditions. Ebrahim Versi, MD, PhD, assumed the roles of CEO and Chairman, while David J. Marguglio transitioned to President and COO.

The company's dedication to combating the opioid crisis was highlighted when its management participated in a White House Roundtable, engaging with key figures in healthcare and policy. Furthermore, DMK, an Adamis subsidiary, secured a grant from the National Institutes of Health for the development of a novel small molecule to treat alcohol use disorder.

In the area of research, Adamis pledged support to the Leiden University Medical Center Anesthesia and Pain Research Unit. The objective is to evaluate the effectiveness of ZIMHI in countering opioid-induced respiratory depression, a critical aspect of opioid overdose.

Financially, Adamis raised approximately $8.0 million through a public offering, reinforcing its capital position. While Q2 2023 revenues remained modest, merger-related transaction costs were reflected in the financials. The company's commitment to responsible research and development is evident in the controlled reduction in R&D expenses.

The Q2 2023 financial highlights also reveal Adamis' determination to grow and diversify its financial base. Despite challenges, the company maintains a focus on innovation, building on its mission to provide effective solutions for critical medical issues. With these developments, Adamis Pharmaceuticals continues to assert its position in the biopharmaceutical landscape.

BioLargo, Inc. (OTCQB:BLGO)

BLGO is an innovative company at the intersection of cleantech and life sciences, providing engineering solutions and pioneering sustainable technologies. The company's core product range addresses a spectrum of environmental challenges, from PFAS contamination and advanced water treatment to odor and VOC control, air quality improvement, energy efficiency, on-site energy storage, and infection control.

Recent developments highlight BioLargo's notable progress. The company reported a remarkable 127% increase in year-to-date revenues compared to the same period last year, demonstrating substantial growth. While there was a temporary decline in quarter-over-quarter sales due to inventory buildup for national retailers, the six-month revenue reached 88% of the total revenue for the previous year.

Dennis P. Calvert, the President and CEO of BioLargo, expressed confidence in the company's trajectory for 2023. He highlighted the success of the Pooph team's national advertising campaign and its expansion into more retail outlets. The team's diligent efforts are aimed at securing contracts with over 20,000 retail stores, reflecting their commitment and expertise.

The financial highlights from the quarterly report offer insights into BioLargo's progress. Consolidated revenues for the three months ending June 30, 2023, reached $1,446,000, marking a 9% increase from the same period in the previous year. While there was a decrease compared to the previous quarter, the company's revenues for the first half of the year showed an impressive 127% increase from the same period in 2022.

Despite the challenges, BioLargo's commitment to growth is evident. Net loss for the second quarter of 2023 was $1,626,000, compared to $1,333,000 in the same period of 2022. The company's net stockholders' equity also saw a positive trend, rising to $4,120,000 at June 30, 2023, from $3,550,000 at the end of March 2023. These financial indicators underscore the company's resilience and its path toward innovation and sustainability.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by  RazorPitch Inc.  and has been retained by  Epazz Inc.  to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer. 

Media Contact
Company Name: Capital Gains Report
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: FLORIDA
Country: United States
Website: https://capitalgainsreport.com/